{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MEK+Mutation&page=2",
    "query": {
      "condition": "MEK Mutation",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MEK+Mutation&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T03:07:05.551Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02296112",
      "title": "Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Stage IIIB Melanoma",
        "Stage IIIC Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "trametinib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2015-01",
      "completion_date": "2021-04-16",
      "has_results": true,
      "last_update_posted_date": "2021-05-28",
      "last_synced_at": "2026-05-22T03:07:05.551Z",
      "location_count": 4,
      "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02296112"
    },
    {
      "nct_id": "NCT04214418",
      "title": "Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastrointestinal Cancer"
      ],
      "interventions": [
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2020-02-12",
      "completion_date": "2022-07-01",
      "has_results": true,
      "last_update_posted_date": "2024-12-18",
      "last_synced_at": "2026-05-22T03:07:05.551Z",
      "location_count": 2,
      "location_summary": "New York, New York • Providence, Rhode Island",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04214418"
    },
    {
      "nct_id": "NCT06104488",
      "title": "A Study of Avutometinib for People With Solid Tumor Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Cancer",
        "CNS Tumors",
        "CNS Tumor, Adult",
        "CNS Tumor, Childhood",
        "MAP Kinase Family Gene Mutation",
        "NF1",
        "Plexiform Neurofibroma",
        "Low-grade Glioma",
        "Optic Pathway Gliomas",
        "Neuroblastoma",
        "Primary Brain Tumor",
        "Solid Tumor",
        "Solid Tumor, Adult",
        "Solid Carcinoma",
        "Central Nervous System Tumor"
      ],
      "interventions": [
        {
          "name": "Avutometinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "3 Years to 30 Years"
      },
      "enrollment_count": 23,
      "start_date": "2023-10-20",
      "completion_date": "2029-10-20",
      "has_results": false,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-05-22T03:07:05.551Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • New York, New York",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06104488"
    },
    {
      "nct_id": "NCT05441514",
      "title": "Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        },
        {
          "name": "Enasidenib Mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2023-04-28",
      "completion_date": "2026-03-19",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-05-22T03:07:05.551Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05441514"
    },
    {
      "nct_id": "NCT01763164",
      "title": "Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic or Unresectable Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "MEK162",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 402,
      "start_date": "2013-07-12",
      "completion_date": "2019-06-04",
      "has_results": true,
      "last_update_posted_date": "2021-03-22",
      "last_synced_at": "2026-05-22T03:07:05.551Z",
      "location_count": 77,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Altamonte Springs, Florida + 46 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Altamonte Springs",
          "state": "Florida"
        },
        {
          "city": "Bonita Springs",
          "state": "Florida"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01763164"
    },
    {
      "nct_id": "NCT01245062",
      "title": "GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "GSK1120212",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 322,
      "start_date": "2010-11-22",
      "completion_date": "2016-12-16",
      "has_results": true,
      "last_update_posted_date": "2018-04-05",
      "last_synced_at": "2026-05-22T03:07:05.551Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Fort Myers, Florida • Athens, Georgia + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01245062"
    },
    {
      "nct_id": "NCT03088176",
      "title": "Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "BRAF Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil",
          "type": "DRUG"
        },
        {
          "name": "Talimogene Laherparep 100 Mil Pfu/Ml 1Ml",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "West Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2017-06-25",
      "completion_date": "2021-06-30",
      "has_results": false,
      "last_update_posted_date": "2020-10-12",
      "last_synced_at": "2026-05-22T03:07:05.551Z",
      "location_count": 1,
      "location_summary": "Germantown, Tennessee",
      "locations": [
        {
          "city": "Germantown",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03088176"
    },
    {
      "nct_id": "NCT01584648",
      "title": "A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 423,
      "start_date": "2012-05-04",
      "completion_date": "2019-02-28",
      "has_results": true,
      "last_update_posted_date": "2021-02-17",
      "last_synced_at": "2026-05-22T03:07:05.551Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01584648"
    },
    {
      "nct_id": "NCT04488003",
      "title": "Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "BRAF Gene Mutation",
        "BRAF Gene Alteration",
        "MEK Mutation",
        "MEK Alteration",
        "MAP2K1 Gene Mutation",
        "MAP2K1 Gene Alteration",
        "MAP2K2 Gene Mutation",
        "MAP2K2 Gene Alteration"
      ],
      "interventions": [
        {
          "name": "Ulixertinib",
          "type": "DRUG"
        },
        {
          "name": "Physician's Choice",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMed Valley Discoveries, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2021-01-07",
      "completion_date": "2023-05-23",
      "has_results": true,
      "last_update_posted_date": "2024-06-04",
      "last_synced_at": "2026-05-22T03:07:05.551Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Newport Beach, California • Newark, Delaware + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04488003"
    },
    {
      "nct_id": "NCT01940809",
      "title": "Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "BRAF V600E Mutation Present",
        "BRAF V600K Mutation Present",
        "Metastatic Melanoma",
        "Stage III Cutaneous Melanoma AJCC v7",
        "Stage IIIA Cutaneous Melanoma AJCC v7",
        "Stage IIIB Cutaneous Melanoma AJCC v7",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2013-08-28",
      "completion_date": "2022-03-04",
      "has_results": false,
      "last_update_posted_date": "2022-03-10",
      "last_synced_at": "2026-05-22T03:07:05.551Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01940809"
    }
  ]
}